Accordingly, we here set out to characterize the suitability of targeting FLT3 with an Fc-optimized mAb for treatment of B-ALL with the aim to expand the usage and benefits of mAb treatment also to the ~70% of B-ALL patients that do not display CD20 expression on leukemic cells [20]. Here, FLT3 is linked to acute lymphoblastic leukemia.